Abstract: A propylene polymer composition is prepared by mixing propylene homo- or co-polymer (A) obtained using a transition metal catalyst compound (h), defined herein, with a co-catalyst, e.g., organoaluminum oxy compound, with an olefin elastomer (D) and another olefin polymer (E), e.g., polyethylene. Alternatively, the combination of propylene polymer (A), olefin elastomer (D) and olefin polymer (E) is prepared by a multi-stage polymerization method. In both cases, the propylene homo- or co-polymer (A) may include a second propylene homo- or co-polymer (A?) wherein the ratio of intrinsic viscosities of propylene polymers (A) and (A?) is in the range of 3 to 30. These propylene polymer compositions are excellent in heat resistance, mechanical strength, tensile elongation at break, etc., and can be used in the fabrication of structural materials, films and sheets.

Abstract: Abstract of the Disclosure A pyrrolesulfonamide derivative, Compound (I), which has strong serotonin-2 receptor antagonistic action and low toxicity and less side effects, and is useful as a therapeutic for circulatory diseases such as ischemic heart diseases, cerebrovascular disturbances and peripheral circulatory disturbances.

Abstract: A propylene polymer composition comprising a propylene polymer prepared by using a zirconocene catalyst having two aryl-substituted indenyl group and having a melt flow rate (MFR) of 0.01 to 30 g/10 min and a second propylene polymer prepared by using a zirconocene catalyst having a melt flow rate (MFR) of 30 to 1,000 g/10 min and, if desired, a soft polymer, a ratio of the MFR of the second propylene polymer to the MFR of the second propylene polymer being not less than 30. These propylene polymer compositions are excellent in heat resistance, mechanical strength, tensile elongation at break, etc., and hence they can be favorably used for various structural materials such as those of automobile and electrical appliances, daily necessaries, various films and sheets.

Abstract: A propylene polymer composition is prepared by mixing propylene homo- or co-polymer (A) obtained using a transition metal catalyst compound (h), defined herein, with a co-catalyst, e.g., organoaluminum oxy compound, with an olefin elastomer (D) and another olefin polymer (E), e.g., polyethylene. Alternatively, the combination of propylene polymer (A), olefin elastomer (D) and olefin polymer (E) is prepared by a multi-stage polymerization method. In both cases, the propylene homo- or co-polymer (A) may include a second propylene homo- or co-polymer (A′) wherein the ratio of intrinsic viscosities of propylene polymers (A) and (A′) is in the range of 3 to 30. These propylene polymer compositions are excellent in heat resistance, mechanical strength, tensile elongation at break, etc., and can be used in the fabrication of structural materials, films and sheets.

Abstract: The ionizer of the present invention comprises a chamber which has an ionization part that ionizes a portion of an ion carrier gas that is supplied to the interior of this chamber, and a blowing part which feeds the ion carrier gas toward a charged body. The ionization part is constructed from an ionization source which is contained in the chamber, and a control device which is connected with this ionization source via a high-voltage cable. Either the generating part of a soft X-ray generating device, the generating part of a low-energy electron beam generating device or the generating part of an ultraviolet radiation generating device is used as the ionization source. The control device, the connecting part between the control device and the high-voltage cable and the connecting part between the ionization source and the high-voltage cable are formed with an explosion-proof structure.

Abstract: A pyrrolesulfonamide derivative having the following formula (I): 1

Abstract: A pyrrolesulfonamide compound having the following formula (I): wherein the ring P represented by is a pyrrole ring having the following structure: wherein A represents alkylene, alkenylene or alkynylene; and Y represents a group in which W represents CH, C═ or N; m stands for 0 or 1 when W is CH or N, or m stands for 1 when W is C═; B represents a specific divalent group; E1 and E2 each independently represents H or lower alkyl; and D represents an aromatic hydrocarbon group or heterocyclic group; l stands for 0 or 1; the dashed line indicates the presence or absence of a bond; and, when the bond is present, Z2 is not present and Z1 represents H but, when the bond is absent, Z1 represents H and Z2 represents OH or Z1 and Z2 are combined together to represent O or a group NOR5, in which R5 represents H, or alkyl, aralkyl or aryl; and R represents H, alkyl, cycloalkyl, cycloalkyl-alkyl or aralkyl.

Abstract: A method of effecting serotonin-2-receptor antagonism in a mammal in need thereof, which includes administering to the mammal an effective amount of the compound of the formula (I), or a pharmaceutically acceptable salt thereof: wherein ring P, the dashed line, A, Y, Z1 and Z2 are defined herein.

Abstract: A plasma display apparatus is equipped with a signal input terminal responsive to a user's application. The plasma display apparatus includes a panel including a pair of substrates, at least one of the substrates is transparent, placed oppositely to each other to form a discharge space in between, and electrodes being provided to the substrates; a display driving circuit block, disposed on a chassis and equipped with at least one signal inputting connector which applies a signal to the panel to perform displaying; and an input signal circuit block detachable to the signal inputting connector of the display driving circuit block.

Abstract: Disclosed are benzothiazine derivatives represented by the following formula (I): wherein the dashed line indicates the presence or absence of a bond; Z represents one of the following groups: in which R1 and R2 individually represent alkyl, aralkyl or the like, R3 represents H, alkyl or the like, R4 represents H, aralkyl or the like, X1, X2 and X3 individually represent O or S, and G represents substituted or unsubstituted ethylene, trimethylene or the like; Q1 and Q2 individually represent H, OH, halogen, alkoxy or the like; A represents alkylene, alkenylene or the like; Y represents CH, C═ or N; when Y is CH, m stands for 0 or 1, n stands for 1 or 2, B represents O, S, carbonyl or the like, when Y is C═, m stands for 1, n stands for 1 or 2, B represents: in which the double bond is linked to Y, R6 represents substituted or unsubstituted aryl or the like; when Y is N, m stands for 0 or 1, n stands for 2 or 3 and B represents carbonyl, sulfonyl

Abstract: A pyrrolesulfonamide compound having the following formula (I): 1

Abstract: It is provided a method for preparing the pyrroloazepine derivatives, especially in optically active form useful as drugs, by low-priced and simple method and in industrial applicable scale, represented by the following formula (I): wherein Z represents optionally substituted phenyl group, which comprises; a process for the asymmetric reduction of ketone compound with metal hydride compound and alcohol compound in the presence of optically active cobalt complex catalyst, and a process for the purification of the resulting compound.

Abstract: A pyrrolesulfonamide derivative having the following formula (I): wherein the ring P represented by  is a pyrrole ring having the following structure: wherein R represents alkyl, cycloalkyl, cycloalkylalkyl or aralkyl; the dashed line indicates the presence or absence of a bond; l stands for 0 or 1; A represents alkylene, alkenylene or alkynylene; and Y represents a group  in which W represents CH, C═ or N; m stands for 0 or 1 when W is CH or N, or m stands for 1 when W is C═; B represents a specific divalent group; E1 and E2 each independently represents H or lower alkyl; and D represents an aromatic hydrocarbon group or heterocyclic group. The compound (I) has strong serotonin-2 receptor antagonistic action and low toxicity and less side effects, and is useful as a therapeutic for circulatory diseases such as ischemic heart diseases, cerebrovascular disturbances and peripheral circulatory disturbances.

Abstract: A method for manufacturing a plasma display apparatus for bonding a panel to a sustaining board with a sufficient bonding area. In a process of bonding the panel to a chassis, the panel is piled on the sustaining board via a heat conducting sheet, then the panel and the chassis are sandwiched between resilient pressuring boards, which are larger than the panel and the chassis. After that, a predetermined pressure is applied from at least one of the pressuring boards, thereby bonding the panel to the chassis via a heat conducting sheet.

Abstract: A method of effecting serotonin-2-receptor antagonism in a mammal in need thereof, which includes administering to the mammal an effective amount of the compound of the formula (I), or a pharmaceutically acceptable salt thereof: 1

Abstract: A propylene polymer composition is prepared by mixing propylene home- or co-polymer (A) obtained using a transition metal catalyst compound (h), defined herein, with a co-catalyst, e.g., organoaluminum oxy compound, with an olefin elastomer (D) and another olefin polymer (E), e.g., polyethylene. Alternatively, the combination of propylene polymer (A), olefin elastomer (D) and olefin polymer (E) is prepared by a multi-stage polymerization method. In both cases, the propylene homo- or copolymer (A) may include a second propylene homo- or co-polymer (A′) wherein the ratio of intrinsic viscosities of propylene polymers (A) and (A′) is in the range of 3 to 30. These propylene polymer compositions are excellent in heat resistance, mechanical strength, tensile elongation at break, etc., and can be used in the fabrication of structural materials, films and sheets.

Abstract: A pyrrolesulfonamide compound having the following formula (I): wherein the ring P represented by is a pyrrole ring having the following structure: wherein A represents alkylene, alkenylene or alkynylene; and Y represents a group in which W represents CH, C═ or N; m stands for 0 or 1 when W is CH or N, or m stands for 1 when W is C═; B represents a specific divalent group; E1 and E2 each independently represents H or lower alkyl; and D represents an aromatic hydrocarbon group or heterocyclic group; l stands for 0 or 1; the dashed line indicates the presence or absence of a bond; and, when the bond is present, Z2 is not present and Z1 represents H but, when the bond is absent, Z1 represents H and Z2 represents OH or Z1 and Z2 are combined together to represent O or a group NOR5, in which R5 represents H, or alkyl, aralkyl or aryl; and R represents H, alkyl, cycloalkyl, cycloalkyl-alkyl or aralkyl.

Abstract: Disclosed are benzothiazine derivatives represented by the following formula (I): 1

Abstract: A method of effecting serotonin-2-receptor antagonism in a mammal in need thereof, which entails administering to the mammal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt thereof: wherein ring P, the dashed line, Z1, Z2, A and Y are as defined herein.

Abstract: It is provided a method for preparing the pyrroloazepine derivatives, especially in optically active form useful as drugs, by low-priced and simple method and in industrial applicable scale, represented by the following formula (I): 1